Adverse events from systemic therapies for psoriasis are common in clinical practice

Journal of Dermatological Treatment

Volumn 17, Issue 5, 2006, Pages 288-293

  Pearce, Daniel J ^a   Higgins, Kristen B ^a   Stealey, Katherine H ^a   Balkrishnan, Rajesh ^b   Crane, Martin M ^c,d   Camacho, Fabian ^a   Fleischer Jr , Alan B ^a   Feldman, Steven R ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c Department of Epidemiology ^*  (United Kingdom)

^d GlaxoSmithKlein

Author keywords

Adverse events; Psoriasis; Side effect; Systemic; Therapy; Treatment

Indexed keywords

ALEFACEPT; BIOLOGICAL FACTOR; CYCLOSPORIN; ETANERCEPT; ETRETIN; ETRETINATE; GOLD SALT; HYDROXYUREA; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; ISOTRETINOIN; METHOTREXATE; METHOXSALEN; RETINOID;

ADULT; AGE DISTRIBUTION; AGED; ANEMIA; ARTHRALGIA; BIOLOGICAL THERAPY; BONE MARROW SUPPRESSION; COMORBIDITY; DEMOGRAPHY; DISEASE DURATION; DYSLIPIDEMIA; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERTENSION; INFECTION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MOOD DISORDER; MYALGIA; NEPHROTOXICITY; POISSON DISTRIBUTION; PRIORITY JOURNAL; PSORIASIS; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; PUSTULOSIS PALMOPLANTARIS; PUVA; RACE; RETROSPECTIVE STUDY; REVIEW; SEX RATIO; SKIN CANCER; SYSTEMIC THERAPY; ULCER; ULTRAVIOLET B RADIATION; UNPLEASANT DREAM; XEROSIS;

ADULT; AGED; BIOLOGICAL PRODUCTS; CYCLOSPORINE; DERMATOLOGIC AGENTS; FEMALE; HUMANS; HYDROXYUREA; MALE; METHOTREXATE; MIDDLE AGED; PSORIASIS; PUVA THERAPY; RETINOIDS; RETROSPECTIVE STUDIES;

EID: 33750135402     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.1080/09546630600920041     Document Type: Review

References (36)

1. Fleischer AB Jr, Feldman SR, Bradham DD. Office-based physician services provided by dermatologists in the United States in 1990. J Invest Dermatol. 1994;102:93-7.
2. Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41(3 Pt 1):401-7.
3. Rapp SR, Exum ML, Reboussin DM, Feldman SR, Fleischer A, Clark A. The physical, psychological and social impact of psoriasis. J Health Psychol. 1997;2:525-37.
4. NPF systemic therapy website. National Psoriasis Foundation 2003 [cited 4 A.D. Jan 12, 2006]. URL: http://www.psoriasis.org/medical/advocacy/ 2003_systemicsdiagram.php
5. Liem WH, McCullough JL, Weinstein GD. Effectiveness of topical therapy for psoriasis: results of a national survey. Cutis. 1995;55:306-10.
6. Menter AM, Abramovitis W. Rational, sequential and combination regimens in the treatment of psoriasis. Dermatol Ther. 1999;11:88-95.
7. Saporito FC, Menter MA. Methotrexate and psoriasis in the era of new biologic agents. J Am Acad Dermatol. 2004;50:301-9.
8. Laburte C, Grossman R, Abi-Rached J, Abeywickrama KH, Dubertret L. Efficacy and safety of oral cyclosporin A (CyA; Sandimmun) for long-term treatment of chronic severe plaque psoriasis. Br J Dermatol. 1994;130:366-75.
9. Feutren G, Abeywickrama K, Friend D, von Graffenried B. Renal function and blood pressure in psoriatic patients treated with cyclosporin A. Br J Dermatol. 1990;122(suppl 36):57-69.
10. Shupack J, Abel E, Bauer E, Brown M, Drake L, Freinkel R, et al. Cyclosporine as maintenance therapy in patients with severe psoriasis. J Am Acad Dermatol. 1997;36(3 Pt 1):423-32.
11. Christophers E, Mrowietz U, Henneicke HH, Farber L, Welzel D. Cyclosporine in psoriasis: A multicenter dose-finding study in severe plaque psoriasis. The German Multicenter Study. J Am Acad Dermatol. 1992;26:86-90.
12. Van Joost T, Bos JD, Heule F, Meinardi MM. Low-dose cyclosporin A in severe psoriasis. A double-blind study. Br J Dermatol. 1988;118:183-90.
13. Ellis CN, Gorsulowsky DC, Hamilton TA, Billings JK, Brown MD, Headington JT, et al. Cyclosporine improves psoriasis in a double-blind study. JAMA. 1986;256:3110-16.
14. Mahrle G, Schulze HJ, Farber L, Weidinger G, Steigleder GK. Low-dose short-term cyclosporine versus etretinate in psoriasis: Improvement of skin, nail, and joint involvement. J Am Acad Dermatol. 1995;32:78-88.
15. Green C, Lakshmipathi T, Johnson BE, Ferguson J. A comparison of the efficacy and relapse rates of narrowband UVB (TL-01) monotherapy vs. etretinate (re-TL-01) vs. etretinate-PUVA (re-PUVA) in the treatment of psoriasis patients. Br J Dermatol. 1992;127:5-9.
16. Gupta AK, Goldfarb MT, Ellis CN, Voorhees JJ. Side-effect profile of acitretin therapy in psoriasis. J Am Acad Dermatol. 1989;20:1088-93.
17. Lassus A, Geiger JM, Nyblom M, Virrankoski T, Kaartamaa M, Ingervo L. Treatment of severe psoriasis with etretin (RO 10-1670). Br J Dermatol. 1987;117:333-41.
18. Dooren-Greebe RJ, Kuijpers AL, Mulder J, De Boo T, Van de Kerkhof PC. Methotrexate revisited: Effects of long-term treatment in psoriasis. Br J Dermatol. 1994;130:204-10.
19. Haustein UF, Rytter M. Methotrexate in psoriasis: 26 years' experience with low-dose long-term treatment. J Eur Acad Dermatol Venereol. 2000;14:382-8.
20. Wollina U, Stander K, Barta U. Toxicity of methotrexate treatment in psoriasis and psoriatic arthritis - short- and long-term toxicity in 104 patients. Clin Rheumatol. 2001;20:406-10.
21. Kumar B, Saraswat A, Kaur I. Short-term methotrexate therapy in psoriasis: A study of 197 patients. Int J Dermatol. 2002;41:444-8.
22. Malatjalian DA, Ross JB, Williams CN, Colwell SJ, Eastwood BJ. Methotrexate hepatotoxicity in psoriatics: Report of 104 patients from Nova Scotia, with analysis of risks from obesity, diabetes and alcohol consumption during long term follow-up. Can J Gastroenterol. 1996;10:369-75.
23. De Rie MA, Meinardi MM, Bos JD. Analysis of side-effects of medium- and low-dose cyclosporin maintenance therapy in psoriasis. Br J Dermatol. 1990;123:347-53.
24. Korstanje MJ, Van de Staak WJ. Long-term treatment of psoriasiswith cyclosporin A- side-effects, minimal effective dose and cyclosporin blood levels. Clin ExpDermatol. 1991;16:8-10.
25. Griffiths CE, Powles AV, McFadden J, Baker BS, Valdimarsson H, Fry L. Long-term cyclosporin for psoriasis. Br J Dermatol. 1989;120:253-60.
26. Grossman RM, Chevret S, Abi-Rached J, Blanchet F, Dubertret L. Long-term safety of cyclosporine in the treatment of psoriasis. Arch Dermatol. 1996;132:623-9.
27. Markham T, Watson A, Rogers S. Adverse effects with long-term cyclosporin for severe psoriasis. Clin Exp Dermatol. 2002;27:111-14.
28. Ho VC, Griffiths CE, Berth-Jones J, Papp KA, Vanaclocha F, Dauden E, et al. Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: a 2-year cohort study. J Am Acad Dermatol. 2001;44: 643-51.
29. Mrowietz U, Farber L, Henneicke-von Zepelin HH, Bachmann H, Welzel D, Christophers E. Long-term maintenance therapy with cyclosporine and posttreatment survey in severe psoriasis: Results of a multicenter study. German Multicenter Study. J Am Acad Dermatol. 1995;33: 470-5.
30. Powles AV, Baker BS, Valdimarsson H, Hulme B, Fry L. Four years of experience with cyclosporin A for psoriasis. Br J Dermatol. 1990;122(suppl 36):13-19.
31. Peluso AM, Bardazzi F, Tosti A, Varotti C. Intermittent cyclosporin A treatment of severe plaque psoriasis. Long-term follow-up of 26 patients. Acta Derm Venereol Suppl (Stockh). 1994;186:90-1.
32. Feldman SR, Fleischer AB Jr, Reboussin DM, Rapp SR, Bradham DD, Exum ML, et al. The economic impact of psoriasis increases with psoriasis severity. J Am Acad Dermatol. 1997;37:564-9.
33. Richards HL, Fortune DG, O'Sullivan TM, Main CJ, Griffiths CE. Patients with psoriasis and their compliance with medication. J Am Acad Dermatol. 1999;41:581-3.
34. Balkrishnan R, Carroll CL, Camacho FT, Feldman SR. Electronic monitoring of medication adherence in skin disease: Results of a pilot study. J Am Acad Dermatol. 2003;49:651-4.
35. Witkowski JA. Compliance: The dermatologic patient. Int J Dermatol. 1988;27:608-11.
36. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life: Results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol. 2001;137:280-4.